This Article Full Text Full Text (PDF) All Versions of this Article: 17/10/1991    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenhagen, M. C. Articles by Rein, T. Search for Related Content PubMed PubMed Citation Articles by Rosenhagen, M. C. Articles by Rein, T.

The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation

Max Planck Institute of Psychiatry (M.C.R., U.S., G.M.W., F.H., T.R.), D-80804 Munich, Germany; Semmelweis University School of Medicine (C.S.), Department of Medical Chemistry, H-1444 Budapest, Hungary; and Max Planck Institute of Biochemistry (F.U.H., J.C.Y.), D-82152 Martinsried, Germany

Address all correspondence and requests for reprints to: Theo Rein, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, Germany. E-mail: theorein{at}mpipsykl.mpg.de.

Cisplatin is an antineoplastic drug that binds to DNA, thereby inhibiting cell division and tumor growth. Cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90). We report that cisplatin dose-dependently inhibited transcriptional activity of the androgen receptor and the glucocorticoid receptor (GR) in transient reporter assays. A truncated, hormone-independent GR was only partially inhibited at significantly higher doses of cisplatin. Cisplatin treatment of neuroblastoma cells led to an immediate inhibition of hormone binding by GR, followed by proteasome-dependent degradation of the receptor. Other Hsp90-regulated proteins, i.e. the phosphokinases raf-1, lck, and c-src, were not affected, indicating a specific functional interference of cisplatin with the steroid receptors GR and androgen receptor. Cisplatin did not elicit a stress response, in contrast to geldanamycin. Immunoprecipitation revealed that cisplatin disrupts binding of GR to Hsp90. Moreover, cisplatin-treated Hsp90 was unable to associate with untreated ligand binding domain of GR. Reticulocyte lysate was able to restore hormone binding of GR in vitro, but not when the lysate was pretreated with geldanamycin. Our data reveal that cisplatin influences steroid receptors also independently of its DNA-mediated effects and, thus, suggest a novel modes of action for this cytostatic drug.

NURSA Molecule Pages Link:

Nuclear Receptors:   GR  |  AR

Ligands:   Hydrocortisone  |  Dihydrotestosterone

This article has been cited by other articles:

				A. Hernandez, G. Lopez-Lluch, J. A. Bernal, P. Navas, and J. A. Pintor-Toro Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90 Mol. Cancer Ther., March 1, 2008; 7(3): 474 - 482. [Abstract] [Full Text] [PDF]

				A. Chakraborty, M. A. Koldobskiy, K. M. Sixt, K. R. Juluri, A. K. Mustafa, A. M. Snowman, D. B. van Rossum, R. L. Patterson, and S. H. Snyder From the Cover: HSP90 regulates cell survival via inositol hexakisphosphate kinase-2 PNAS, January 29, 2008; 105(4): 1134 - 1139. [Abstract] [Full Text] [PDF]

				D. L. Marrocco, W. D. Tilley, T. Bianco-Miotto, A. Evdokiou, H. I. Scher, R. A. Rifkind, P. A. Marks, V. M. Richon, and L. M. Butler Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol. Cancer Ther., January 1, 2007; 6(1): 51 - 60. [Abstract] [Full Text] [PDF]

				M. Moayeri, J. F. Wiggins, R. E. Lindeman, and S. H. Leppla Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2658 - 2665. [Abstract] [Full Text] [PDF]

				R. K. Allan, D. Mok, B. K. Ward, and T. Ratajczak Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90: EVIDENCE THAT COUMARIN ANTIBIOTICS DISRUPT Hsp90 DIMERIZATION J. Biol. Chem., March 17, 2006; 281(11): 7161 - 7171. [Abstract] [Full Text] [PDF]

				R. Bagatell and L. Whitesell Altered Hsp90 function in cancer: A unique therapeutic opportunity Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030. [Abstract] [Full Text] [PDF]